Wet macular degeneration

This study is checking the long-term safety of an implant called OTX-TKI (axitinib) for people with wet age-related macular degeneration (AMD). The implant is placed in the eye and slowly releases medicine to control the disease. About 850 people who already completed two years o…

This study tests a new medicine called tiespectus (EYE201) for wet age-related macular degeneration, a leading cause of vision loss. About 960 people will receive either tiespectus or the standard treatment aflibercept via eye injections. The goal is to see if tiespectus can impr…

This study tests a new drug called tiespectus (MK-8748) against the current standard treatment, aflibercept, for people with wet age-related macular degeneration (AMD). About 960 participants will receive injections into the eye and be followed for a year to see if tiespectus can…

This study tests whether injecting a person's own bone marrow stem cells into or near the eye can help treat various retinal and optic nerve diseases, including age-related macular degeneration, retinitis pigmentosa, and glaucoma. Participants receive stem cell injections via dif…

This early-stage trial tests a new medicine called EYC-0305, given as an eye injection every 24 weeks, in 30 people aged 50 and older with wet age-related macular degeneration (AMD). The main goal is to check if the treatment is safe and tolerable. Researchers will also measure h…

This study tests a gene therapy called ABBV-RGX-314 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if a single treatment can reduce the need for frequent eye injections while keeping vision stable. About 561 adults a…

This study looks at switching people with wet age-related macular degeneration (AMD) to a higher dose (8 mg) of the drug aflibercept. The goal is to see if it can extend the time between eye injections while still controlling the disease. Researchers will compare injection interv…

This study tests a refillable eye implant (Port Delivery System) that slowly releases the drug ranibizumab to treat wet age-related macular degeneration. The implant is refilled every 36 weeks, potentially reducing the need for frequent eye injections. About 250 participants who …

This study looks at 100 people with wet age-related macular degeneration (AMD) who have been getting regular eye injections with older drugs. They will switch to a newer drug called faricimab. The goal is to see if faricimab can extend the time between injections, meaning fewer t…

This phase 3 trial tests whether a new drug called ABP 938 works as well as the approved treatment Eylea HD for wet age-related macular degeneration, a leading cause of vision loss. About 304 people aged 50 and older with untreated wet AMD will receive injections of either drug i…

This Phase 2 trial tests an experimental drug called EYE103 (Restoret) in 160 people with wet age-related macular degeneration or macular edema from a branch retinal vein occlusion. Participants receive three eye injections of either a low or high dose of EYE103, spaced four week…

This phase 3 study tests a single injection of Ixo-vec gene therapy against standard aflibercept injections in 284 people with wet AMD. The goal is to see if Ixo-vec can maintain or improve vision while reducing the need for repeated eye injections. Participants must be at least …

This observational study will follow 300 people with wet age-related macular degeneration (nAMD) who receive aflibercept 8 mg injections as part of their routine care. Researchers want to see how well the drug improves vision and reduces retinal swelling over 12 months, and what …

This study is testing a refillable eye implant that delivers the drug ranibizumab to treat wet age-related macular degeneration (AMD). The main goal is to see if the implant affects the cells on the inner surface of the cornea. About 188 people with wet AMD will receive the impla…

This study tests a small, refillable implant placed in the eye that slowly releases medication for wet age-related macular degeneration (nAMD). It aims to see if refilling the implant every 24 weeks works as well as getting a standard eye injection every 4 weeks. About 68 Chinese…

This study tests a gene therapy called Ixo-vec in the second eye of people with wet age-related macular degeneration (AMD) in both eyes. Fifteen adults aged 50 and older will receive a single injection in the second eye and be followed for about 5 years. The goal is to see if the…

This study is checking the long-term safety of a small implant placed in the eye that slowly releases medicine to treat wet age-related macular degeneration, a condition that can cause rapid vision loss. About 1,000 people who have already used the implant in earlier studies will…

This study tests the drug faricimab (Vabysmo) in 100 people aged 50+ with wet age-related macular degeneration who have a specific type of harmful material under their retina. The goal is to see if the drug can clear that material by week 16. Participants receive injections into …

This Phase 3 trial tests whether people with wet age-related macular degeneration can use a home optical coherence tomography (OCT) device to guide when they need eye injections, instead of following a fixed schedule. 600 participants will either receive faricimab injections on a…

This phase 3 trial tests whether adding surgery (vitrectomy, clot-busting drug, and gas bubble) to standard anti-VEGF injections can improve vision more than injections alone for people with a macular bleed from wet AMD. About 210 participants across Europe will be randomly assig…

This early-stage trial tests an experimental drug called BBC1501, given as an injection into the eye, for people with wet age-related macular degeneration (nAMD). The main goal is to check safety and tolerability in 18 volunteers aged 50 and older who have already received standa…

This early-phase trial tests a new drug called PRL3-zumab in 15 people with wet age-related macular degeneration (nAMD) who have not improved with standard treatments. The drug is given by IV every two weeks for three doses. The study will check for safety and any signs that visi…

This study tests a one-time gene therapy called RGX-314 for wet age-related macular degeneration (AMD), a leading cause of vision loss. About 714 adults aged 50-89 who currently need regular eye injections will receive either the gene therapy or standard treatment. The goal is to…

This Phase 3 trial tests a single injection of 4D-150, a gene therapy, in 480 adults with wet age-related macular degeneration (AMD). The goal is to see if one treatment can maintain or improve vision and reduce the need for standard anti-VEGF injections like Eylea. Participants …

This study tests whether an oral medication (doxycycline) can help people with wet age-related macular degeneration (AMD) who still have fluid under their retina despite standard eye injections. About 50 participants will receive either doxycycline or a placebo for several months…

This study tests a device called PRIMA, which is implanted under the retina to help people with inherited retinal diseases like Stargardt disease and retinitis pigmentosa see better. The trial will enroll 5 adults with severe central vision loss and measure improvements in visual…

This early study tests a single injection of LX111 gene therapy in 10 people aged 50 or older with wet age-related macular degeneration (nAMD). The goal is to see if it is safe and can help control the disease, possibly reducing the need for frequent eye injections. Participants …

This Phase 3 trial tests a single injection of LX102 gene therapy under the retina for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. About 332 participants will receive either LX102 or standard aflibercept injections. The goal is to see i…

This study looks at how well a higher dose (8mg) of the drug Aflibercept (Eylea) works in the first two months for people with wet age-related macular degeneration, a leading cause of vision loss. Researchers will track fluid changes in the retina and vision improvements in 50 pa…

This study tests a gene therapy called 4D-150 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if a single injection into the eye can safely reduce the need for regular anti-VEGF shots. About 215 adults aged 50 and old…

This study tests a new drug called IBI302, given as an eye injection, for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if it can prevent further vision decline over 52 weeks. About 800 adults aged 50 and older with act…

This study looks at how well a biosimilar drug called Yesafili works for people with wet age-related macular degeneration (AMD). About 54 participants will switch from the standard drug Eylea to Yesafili. Doctors will check vision and eye health to see if the biosimilar is a safe…

This study tests a new drug called SAR402663, given as a single injection into the eye, for people with wet age-related macular degeneration (AMD). The goal is to see if one dose can safely control the disease and reduce the need for frequent anti-VEGF injections. About 66 partic…

This study tests whether faricimab (Vabysmo) injections given every 12-16 weeks can maintain stability in people with wet age-related macular degeneration (AMD) after an initial series of loading doses. The trial will enroll 40 adults over 50 with active wet AMD. The main goal is…

This study tests an experimental oral tablet called HX9428 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The trial will enroll 198 adults aged 50–85 to check the drug's safety, how the body processes it, and whether it can improve eye…

This study tests an experimental drug called SCT520FF for wet age-related macular degeneration (AMD), a leading cause of vision loss. About 82 adults aged 45 to 80 will receive either SCT520FF or an existing treatment (EYLEA) via eye injections. Researchers will check safety, sid…

This study is testing a home-based eye-tracking system called AVIGA to see if it can detect when wet age-related macular degeneration (AMD) comes back. Sixty adults aged 50-99 who are being treated for wet AMD will use the AVIGA device at home, and its accuracy will be compared t…

This study tests a new eye imaging device (VG200D OCT) that takes detailed pictures of the retina. It compares these images to standard dye-based images (FA/ICGA) to see if the new device works just as well. About 30 adults with retina problems will take part. The goal is to see …

This study tests a special camera that takes detailed images of the retina using many wavelengths of light. Researchers hope it can find early signs of eye diseases like age-related macular degeneration, diabetic retinopathy, and glaucoma. About 1,000 adults in Melbourne, Austral…

This study is testing a new eye imaging device called the VG200D, which uses advanced technology to take detailed pictures of the eye. Researchers want to see if it works as well as a standard device for measuring parts of the eye in people with glaucoma, retina problems, corneal…

This study tests whether adding emotional regulation therapy (ERT) to standard low vision rehabilitation (LVR) helps people with inherited retinal diseases who feel anxious or distressed about their vision. About 180 participants will receive LVR, which includes free vision-enhan…

This study looks at whether disulfiram (Antabuse), a drug used for alcohol use disorder, can improve vision in people with retinal degeneration (like macular degeneration or retinitis pigmentosa). Researchers believe it may calm overactive cells in the retina. The study involves …

This study is creating a large collection of health information and biological samples (like blood, saliva, and eye tissue) from people with and without retinal diseases. Researchers aim to use this database to better understand conditions like age-related macular degeneration an…

This international study aims to collect genetic and health information from 1,500 people with rare inherited retinal diseases like retinitis pigmentosa. It has two parts: a registry to gather genetic and vision data, and a natural history study that follows participants over tim…

This study screens people with eye diseases to see if they can join other research studies at the National Eye Institute. No treatment is given. Participants undergo eye exams, blood tests, and other procedures to diagnose or evaluate their condition. The goal is simply to determ…

This study interviews 30 patients with wet age-related macular degeneration to understand their views on gene therapy. Researchers want to know if the benefits outweigh the risks of this irreversible treatment, and how patients make decisions about complex therapies. The goal is …

This study will analyze health records from 2009 to 2024 to find out how many people in Germany have three serious eye conditions: wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Researchers will look at data from two large German health …

This study tests a special camera that takes super-detailed pictures of the back of the eye (the retina). The goal is to see if this technology can find eye diseases earlier than standard methods. Up to 1,000 people aged 12 and older, with or without eye disease, will have their …

This study looks at three drugs (bevacizumab, ranibizumab, and aflibercept) used to treat age-related macular degeneration (AMD), a leading cause of blindness in older adults. Researchers will analyze costs and quality of life for 600 patients in France to see which treatment off…

This study is collecting information from 850 people with wet age-related macular degeneration or diabetic macular edema who are being treated with faricimab (VABYSMO) in routine clinical practice. Over two years, researchers will track vision changes, treatment schedules, and sa…

This study aims to learn more about eye diseases by observing and providing standard care to up to 1,000 people over 5 years. Participants receive regular eye exams, tests, and treatments as needed. The goal is to better understand how eye diseases progress and are inherited, not…

This study looks at how well people with retinal diseases like retinitis pigmentosa and Stargardt's disease see in the dark. Researchers want to find out if measuring dark adaptation can help detect and track these conditions. Healthy volunteers and people with retinal disease ag…

This study uses a special camera (adaptive optics) to take detailed pictures of the back of the eye in people with inherited retinal diseases. Researchers want to see how individual cells change over time and after treatments. About 200 participants aged 5 to 70 will be observed,…

This study enrolls 25 people with severe retinal diseases like retinitis pigmentosa and Stargardt disease to test new ways of measuring visual function. Researchers will evaluate how well participants can perform various vision tests, such as navigating obstacles or detecting lig…

This study tests whether artificial intelligence can create simple summaries of eye doctor notes that are easier for patients to understand. About 460 English-speaking adults receiving eye care will get either standard notes or notes plus an AI-generated plain language summary. P…

This study gathers eye scan images from 180 people with healthy eyes or eye diseases like glaucoma and retinal disease. The goal is to collect data using a new optical coherence tomography (OCT) device called A10900. No treatment or medication is given. The information will help …

This study aims to understand the natural bacteria living on the surface of the eye in both healthy people and those with certain eye conditions. Researchers will collect eye swabs from 500 adults in middle Tennessee to build a database of what a normal eye microbiome looks like.…

This study tests a new 4D microscope-integrated OCT system for the first time in people during eye surgery. Researchers want to see if the system is easy to use, safe, and can clearly show eye structures. Five adults having eye surgery will take part. The goal is to improve imagi…

This study looks at whether sinusitis (sinus infection) is common in people with wet age-related macular degeneration (AMD) who need many eye injections. Researchers will screen 200 participants for sinusitis and treat it if found. They will then check if sinusitis treatment redu…

This study looks at how color vision changes over time in people with inherited retinal diseases (IRDs). Researchers will study 200 participants, including those with IRDs and healthy volunteers, to see how color vision loss relates to changes in the retina's structure. They are …

This study gathers standard eye movement and pupil data from 200 healthy volunteers, children, and people with eye or brain conditions using a VR headset called neos™. The headset shows images and tracks where participants look, how their pupils react, and how their eyes move. Th…

This study aims to find out why 20-40% of people with wet age-related macular degeneration (AMD) don't respond well to standard anti-VEGF injections. Researchers will collect fluid from inside the eye of 117 patients and compare those who respond well to treatment with those who …

This phase 3 trial is testing whether a person's genetic makeup influences how well they respond to two standard drugs for wet age-related macular degeneration: ranibizumab and bevacizumab. About 630 patients will receive one of the two drugs and be followed for three years. The …

This study tests a new, more comfortable eye camera (WiSLO) designed for children and adults. Researchers want to see if it takes better pictures and is less bothersome than current cameras. About 42 people with or without eye disease will have their eyes photographed with both t…